Eton Pharmaceuticals: Alkindi Sprinkle Leads Growth In Orphan Disease Portfolio
Eton Pharmaceuticals' Alkindi Sprinkle is their lead orphan product, addressing a $100M opportunity. Click here to read why ETON stock is a Buy.
Source: seekingalpha.com